Form 4: Abbott Laboratories Director Michael F. Roman Reports Acquisition of Restricted Stock Units

Director Michael F. Roman reports acquisition of 1,866 restricted stock units of Abbott Laboratories, convertible to common shares upon certain events.

Summary

• On April 26, 2024, Michael F. Roman, a director of Abbott Laboratories, reported the acquisition of 1,866 restricted stock units (RSUs).
• These RSUs were awarded under the Abbott Laboratories 2017 Incentive Stock Program.
• The RSUs will be paid out in Abbott common shares on a one-to-one basis upon the director's separation from service, death, or a change in control.
• Following the transaction, Roman directly owns 6,843 common shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of RSUs is a standard part of executive compensation and aligns the director's interests with the company's performance. There are no indications of negative events or concerns.

Positives

• The acquisition of restricted stock units aligns the director's interests with the long-term performance of Abbott Laboratories.
• The incentive stock program is designed to reward key personnel and incentivize continued service.

Future Outlook

The restricted stock units will convert to common shares upon the occurrence of specific events such as separation from service, death, or a change in control, indicating a future potential increase in the director's shareholding.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders, such as directors and officers, in their company's stock. This filing indicates that a director has received additional compensation in the form of equity.

Stakeholder Impact

• The acquisition of restricted stock units by a director can positively influence shareholder confidence by aligning management's interests with those of the shareholders.

Key Dates